Collaborations & Alliances

Pfizer Inks $1.25 Billion Deal with 3SBio for Global Rights to Cancer Drug

SSGJ-707 has shown initial efficacy and safety data in a promising class of cancer medicines.

Author Image

By: Charlie Sternberg

Associate Editor

Pfizer Inc. has secured an exclusive global licensing agreement with 3SBio, Inc., a leading Chinese biopharma, for SSGJ-707, a bispecific antibody targeting PD-1 and VEGF. The deal, announced today, grants Pfizer rights to develop, manufacture, and commercialize the drug worldwide, excluding China, with an option to expand into the Chinese market. SSGJ-707, currently in clinical trials in China for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors, has shown p...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters